Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides a source of potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Sodium chloride provides sodium and chloride ions, which are necessary for maintaining extracellular fluid volume and osmolality.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
FDA-approved: Replacement therapy for potassium and sodium deficiencies, maintenance of electrolyte balance in parenteral nutrition, and as a source of electrolytes in intravenous fluids.,Off-label: Management of hypokalemia, correction of hyponatremia, and prevention of electrolyte imbalances in patients unable to take oral fluids.
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion: 0.037% potassium chloride in 0.9% sodium chloride solution; rate not to exceed 10 m Eq/hour (or 10 mmol/hour) potassium; typical adult dose 20-40 m Eq per day, adjusted based on serum potassium levels.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Potassium: Not applicable as endogenous ion with tight homeostatic control; administered potassium distributes rapidly and is eliminated with a functional half-life of about 1-2 hours in the central compartment due to redistribution and renal excretion, but total body potassium turnover half-life is approximately 20-30 days. Sodium: Not applicable; administered sodium is rapidly equilibrated and renally regulated.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Potassium and sodium are not metabolized; they are excreted primarily by the kidneys. Potassium is also excreted in feces and sweat. Sodium is mainly excreted in urine under the regulation of aldosterone and other hormones.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal excretion of potassium is the primary route (approximately 90% of daily intake), with minimal fecal loss (about 10%). The sodium component is also predominantly renally excreted, with >99% of filtered sodium reabsorbed under normal conditions.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Potassium: Not significantly protein-bound (<1%). Sodium: Not significantly protein-bound (<1%).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Potassium: Total body water (approximately 0.5 L/kg) with 98% intracellular; Vd for extracellular potassium is about 0.2 L/kg. Sodium: Primarily extracellular fluid, Vd approximately 0.2-0.3 L/kg.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR 20-50 m L/min: reduce maintenance dose by 25-50%; GFR <20 m L/min: avoid use or use with extreme caution, dose reduction of 50-75% and frequent monitoring of serum potassium.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific dose adjustments for Child-Pugh class A, B, or C; however, monitor serum potassium closely due to potential metabolic disturbances.
No dosage adjustment required for hepatic impairment.
Intravenous infusion: 0.2-0.5 m Eq/kg/hour (max 1 m Eq/kg/day) for maintenance; for replacement, 0.3-1 m Eq/kg/dose based on serum potassium deficit; rate not to exceed 0.5-1 m Eq/kg/hour.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Initiate at low end of adult dosing; monitor renal function and serum potassium more frequently due to age-related decline in renal function and increased risk of hyperkalemia.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Administration may cause hyperkalemia, especially in patients with renal impairment, or if given too rapidly. Hypernatremia may occur with excessive sodium administration. Use with caution in patients with heart failure, renal insufficiency, or conditions predisposing to fluid overload. Monitor serum electrolytes and fluid balance. Do not administer unless solution is clear and container is intact.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperkalemia, hypernatremia, severe renal impairment with oliguria or anuria, uncompensated heart failure, metabolic alkalosis, and known hypersensitivity to any component.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes) unless directed by your healthcare provider, as they may increase risk of hyperkalemia. Salt substitutes often contain potassium chloride and should be avoided.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER: Potassium chloride is a normal constituent of body fluids and is essential for cellular function. At physiological concentrations, no teratogenic effects are expected. However, hyperkalemia may occur with excessive administration, which can cause maternal cardiac arrhythmias and potentially fetal distress. No specific fetal malformations are associated with potassium chloride at replacement doses. First trimester: No known teratogenic risk with appropriate use. Second and third trimesters: Use cautiously to avoid hyperkalemia, which may affect fetal heart rate; monitor maternal serum potassium levels.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Potassium chloride is a normal component of breast milk at concentrations around 13 m Eq/L. Administration of potassium chloride injection does not significantly alter breast milk potassium levels. The M/P ratio is approximately 1.0, reflecting passive distribution. Use is considered compatible with breastfeeding; no adverse effects on nursing infants are anticipated when maternal serum potassium is maintained within the normal range.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy induces a state of expanded extracellular fluid volume and increased renal blood flow, leading to enhanced clearance of potassium. However, potassium chloride dosing adjustments are generally not required in pregnancy unless the patient develops hypokalemia or hyperkalemia. Dose should be guided by serum potassium levels, which may be slightly lower in pregnancy due to dilutional effects. Avoid excessive potassium administration to prevent hyperkalemia, especially in patients with impaired renal function or preeclampsia.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This solution is used for maintenance hydration and to correct or prevent hypokalemia. Monitor serum potassium levels and renal function. Do not administer undiluted; ensure compatibility with concurrent medications. Use with caution in patients with renal impairment, adrenal insufficiency, or digitalis toxicity. Rapid infusion may cause hyperkalemia and cardiac arrest. Maximum infusion rate: 10 m Eq/h (0.037% KCl = 5 m Eq/L).
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This medication is a potassium supplement given through your vein to maintain normal potassium levels.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking any other medications.,You may feel warmth, tingling, or pain at the IV site; report any discomfort immediately.,Do not stop treatment abruptly without consulting your doctor.,Inform your provider if you develop muscle weakness, irregular heartbeat, or numbness.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides a source of potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Sodium chloride provides sodium and chloride ions, which are necessary for maintaining extracellular fluid volume and osmolality.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion: 0.037% potassium chloride in 0.9% sodium chloride solution; rate not to exceed 10 m Eq/hour (or 10 mmol/hour) potassium; typical adult dose 20-40 m Eq per day, adjusted based on serum potassium levels.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER: Potassium chloride is a normal constituent of body fluids and is essential for cellular function. At physiol. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.